TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16540840
Drug: Caffeinated drink
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeinated drink (5 mg x kg(‐1))
Study: 20880169
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of oral revaprazan daily for 7 days
Study: 6754384
Drug: Betamethasone 9
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone 9 mg (Celeston Chronodose)
Study: 19036671
Drug: Tigecycline 100
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline 100 mg/day (100 mg initial dose, then 50 mg intravenously twice daily)
Study: 16251309
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vancomycin 2 g/day (1 g intravenously twice daily) and aztreonam 4 g/day (2 g intravenously twice daily)
Study: 11503006
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg
Study: 7358867
Drug: Parenteral Nefopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral Nefopam
Study: 2619149
Drug: Ketorolac solution
Normalized name: ketorolac Injectable Solution
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac solution 0.5% eye drops
Study: 29798375
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone (10 mg/ml)
Study: 25773936
Drug: Intravenous contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous contrast enhanced-CT (CE-CT)
Study: 19300235
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of trimethoprim‐sulfamethoxazole at urinary catheter removal
Study: 12037783
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone 1,000 mg for three consecutive days
Study: 29952137
Drug: Combined external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined external resistance (2-20 cmH2 O/L/sec)
Study: 3095698
Drug: Amantadine 100
Normalized name: amantadine 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 100 mg/day (Al)
Study: 31089818
Drug: Azithromycin (AZM)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (AZM) combined with steroid therapy
Study: 1627763
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta administered intravenously (i.v.) once a week
Study: 10738641
Drug: Vincamine test
Normalized name: vincamine
DrugBank: Vincamine (DB13374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincamine test product (60 mg single dose)
Study: 9462488
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch for 10 weeks as an adjunct to brief counseling
Study: 29259181
Drug: Omega-3 capsules
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 capsules (2 g/day for 8 weeks)
Study: 9701531
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg
Study: 8678098
Drug: Cefepime 2
Normalized name: cefepime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 2 g every 12 hours
Study: 8678098
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g every 8 hours
Study: 20975611
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor group
Study: 26040200
Drug: Double antibiotic
Normalized name: Double Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double antibiotic paste (DAP) 500 mg ml(‐1) + EDTA
Study: 10468965
Drug: Open GH
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open GH treatment after placebo
Study: 8862492
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day clomiphene citrate for 3 days
Study: 31175696
Drug: Hydrogen peroxide
Normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrogen peroxide 6% solution under occlusion for one hour daily for 6 weeks
Study: 31175696
Drug: Hydrogen peroxide
Normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrogen peroxide 3% solution
Study: 19656577
Drug: Adjunctive aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive aripiprazole (n=373)
Study: 10220205
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Q10 daily for 3 months
Study: 7637151
Drug: 25g glucose
Normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25g glucose infusion in an hour (glucose group)
Study: 10212537
Drug: Immediate or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate or delayed-immediate implant placement techniques
Study: 26963600
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT)
Study: 26591679
Drug: Medicine
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medicine
Study: 18547996
Drug: Erythropoiesis stimulating
Normalized name: Erythropoiesis stimulating agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis stimulating agents (epoetin) treatment in anemic patients (23 patients)
Study: 22148098
Drug: 75 mg/day
Normalized name: Lyllana 0.075 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/day aspirin
Study: 2256579
Drug: Low Group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Group I allergenic house dust (0.66 micrograms/g)
Study: 31882240
Drug: Tibetan medicated
Normalized name: ibritumomab tiuxetan
DrugBank: Ibritumomab tiuxetan (DB00078)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tibetan medicated bathing therapy in combination with conventional rehabilitation
Study: 8534629
Drug: Kabi 2161
Normalized name: immunoglobulin G, human Injectable Solution [Kabiglobulin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kabi 2161 (600 mg) tablets, 1 four times daily
Study: 8534629
Drug: Kabi 2161
Normalized name: immunoglobulin G, human Injectable Solution [Kabiglobulin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kabi 2161 (600 mg) tablets, 2 twice daily
Study: 24807330
Drug: Indomethacin and
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin and antibiotics
Study: 10530636
Drug: Desipramine hydrochloride
Normalized name: Desipramine Hydrochloride
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine hydrochloride (50 to 150 mg/d)
Study: 2979286
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg nocte
Study: 26114240
Drug: Aripiprazole lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aripiprazole lauroxil 441 mg
Study: 25765456
Drug: 1 min
Normalized name: ZINC OXIDE 182.3 mg in 1 mL TOPICAL CREAM [Mini Hueguard 3-in-1 Mineral SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 min treatment
Study: 10716688
Drug: Alpha interferon
Normalized name: Natural alpha interferon
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha interferon 10 million units three times weekly for 16 weeks (n=69)
Study: 90215
Drug: Disodium dichloromethylene
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disodium dichloromethylene diphosphonate 1600 mg/day
Study: 28914750
Drug: Live-attenuated influenza
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live-attenuated influenza vaccine (LAIV)
Study: 12038039
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei and L. acidophilus strains CERELA
Study: 1974513
Drug: Chronic administration
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic administration of carvedilol
Study: 10485531
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received salt solution only
Study: 1657505
Drug: Simultaneous injection
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous injection of leucine
Study: 15825072
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg twice per day
Study: 8431099
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of methylphenidate per day
Study: 27141626
Drug: Intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia (IVA)
Study: 8673823
Drug: Ivermectin treatment
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin treatment (multiple doses)
Study: 28345814
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg once daily plus exenatide 2 mg once weekly
Study: 29066437
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 2000 IU (50 μg) daily
Study: 23850610
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) administration of LIPO-4 vaccine
Study: 16282845
Drug: Sustained-release bupropion
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release bupropion
Study: 27793204
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of iron fumarate supplements at one to two daily doses of 100 mg each
Study: 1684678
Drug: Ketanserin (KS)
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (KS) 40-80 mg daily
Study: 15477398
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 to 80 mg daily
Study: 1684678
Drug: Beta-adrenergic blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic blocker propranolol (PP)
Study: 6122752
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of a beta‐blocker
Study: 1289514
Drug: Verapamil 240
Normalized name: verapamil 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 240 mg SR
Study: 7286051
Drug: Chlorthalidone 25
Normalized name: chlorthalidone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg
Study: 3890732
Drug: Single-dose tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose tetracycline (2 g)
Study: 3890732
Drug: Multi-dose tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multi-dose tetracycline (500 mg four times per day for 10 days)
Study: 27720506
Drug: 0.2mg oral
Normalized name: NALDEMEDINE 0.2MG ORAL TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2mg oral clonidine one hour before the operation in addition to standard anesthesia procedure
Study: 17274708
Drug: Control SEI
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control SEI with dual acid-etched surface without treatment
Study: 15998659
Drug: FAT infusion
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAT infusion (long-chain triglyceride emulsion, 2.8 kcal/min)
Study: 10656432
Drug: Melphalan 40
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 40 mg/m2 (n = 6)
Study: 1993621
Drug: Prolonged treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged treatment elapsed days (14 days beyond the protocol prescription)
Study: 9828914
Drug: PD-GHRH test
Normalized name: Poly Hist PD
DrugBank: Thonzylamine (DB11235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-GHRH test with HC (80 mg/day for 1 day)
Study: 6988173
Drug: Oral clenbuterol
Normalized name: clenbuterol
DrugBank: Clenbuterol (DB01407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clenbuterol at 20 to 30 micrograms 3-times daily
Study: 10333820
Drug: Simethicone alone
Normalized name: Simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone alone (125 mg)
Study: 6358654
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CyA) with low-dose steroids
Study: 31400624
Drug: Adjunctive riluzole
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive riluzole
Study: 2566222
Drug: UVB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB treatment
Study: 17263737
Drug: Intranasal clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal clonidine
Study: 18652321
Drug: Routine western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine western medicine without acupuncture (Control)
Study: 8607306
Drug: Epidural group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural group (15 ml of bupivacaine 0.75% via thoracic epidural route)
Study: 8607306
Drug: Papaveretum group
Normalized name: papaveretum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaveretum group (20‐30 mg of papaveretum i.v.)
Study: 12741933
Drug: Control site
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control site (1 mL saline without dexamethasone)
Study: 12741933
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg dexamethasone in 1 mL saline through one subcutaneous site (test site)
Study: 9100588
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose L (0.2 mg/kg) in fasted obese
Study: 24030130
Drug: TEAM intervention
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TEAM intervention (6-month intervention with scheduled visits, Brief Medication Questionnaires, and toolkits)
Study: 28645960
Drug: Physiotherapy (PT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiotherapy (PT) group received seven PT sessions (one preoperative and six postoperative) incorporating education, manual therapy, and a progressive rehabilitation programme of home, aquatic, and gym exercises.
Study: 30590587
Drug: Fasting insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fasting insulin
Study: 7537110
Drug: Interleukin-6 (IL-6)
Normalized name: autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6) (also termed ssCART-19 cells)
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-6 (IL-6) administered before chemotherapy.
Study: 7537110
Drug: Interleukin-6 (IL-6)
Normalized name: autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6) (also termed ssCART-19 cells)
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-6 (IL-6) administered during chemotherapy.
Study: 7574752
Drug: Intraperitoneal cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal cisplatin (CDDP) chemotherapy, 100 mg of CDDP and 300 ml of saline administered intraperitoneally just after operation for curatively resected patients; same doses for patients with ascites after removal of fluid.
Study: 340327
Drug: Intensive regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive regimen of Al‐Mg antacid
Study: 14521760
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (group B)
Study: 7598243
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg
Study: 14523485
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C and E (600 mg/day each)
Study: 28125093
Drug: L-thyroxine (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-thyroxine (L-T4) supplementation at a dose of 5 μg kg-1 day-1
Study: 26559637
Drug: Vonoprazan 10
Normalized name: vonoprazan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 10 or 20 mg as maintenance therapy
Study: 7377745
Drug: Sulfadiazine (SD)
Normalized name: Sulfadiazine
DrugBank: Sulfadiazine (DB00359)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfadiazine (SD) 250 mg twice daily
Study: 15221063
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (tailored resection, including microsurgical lesionectomy, lesionectomy plus cortectomy, and hippocampectomy)
Study: 16428539
Drug: SCH 1
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 1 mg/kg ideal body weight
Study: 16428539
Drug: SCH 1
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 1 mg/kg total body weight
Study: 15571211
Drug: Febuxostat 10
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 10 mg to 120 mg
Study: 29121356
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of 0.5 mL cefazolin-balanced salt solution (0.3 mL cefazolin and 0.2 mL balanced salt solution)
Study: 24831447
Drug: Baseline VL
Normalized name: VL-2397
DrugBank: VL-2397 (DB17796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline VL >100,000 copies/ml (N = 122)
Study: 28855078
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment with prasugrel for 12 months)
Study: 18703188
Drug: Local application
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application of PRP gel
Study: 2532868
Drug: Loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 10 mg
Study: 17688969
Drug: docetaxel monotherapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel monotherapy
Study: 21224289
Drug: Reconstituted high-density
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstituted high-density lipoprotein (rHDL) infusion
Study: 11812877
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (3 g/day)
Study: 2192839
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate lozenges (4.5 mg zinc)
Study: 11196741
Drug: New measles-mumps-rubella
Normalized name: MEASLES/MUMPS/RUBELLA VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: New measles-mumps-rubella (MMR) vaccine (Priorix, SmithKline Beecham)
Study: 15757851
Drug: Levothyroxine (LT4)
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (LT4) treatment in patients with SH
Study: 9498653
Drug: Cholesterol supplementation
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol supplementation of 800 mg/day
Study: 1512807
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment approaches; specific details not available.
Study: 7733034
Drug: Animal-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-protein diet with vitamin B-6 intakes of 0.5, 1.0, 1.5, and 2.0 mg/d
Study: 2439815
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg
Study: 23283539
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment and exercises
Study: 31190359
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1,000 mg omega-3 fatty acids, twice a day for 12 weeks)
Study: 1514335
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (Group A) + No-treatment control (Group B)
Study: 8370085
Drug: Floating (F)
Normalized name: Floating little wheat
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floating (F) hydrophilic matrix capsules